Protein breakdown in cancer cachexia

Seminars in Cell and Developmental Biology

Volumn 54, Issue , 2016, Pages 11-19

  Sandri, Marco ^a,b,c,d  

^a VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c CNR   (Italy)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

Atrophy; Autophagy; Cancer cachexia; FoxO; Lysosome; Muscle; Myostatin; Proteasome; Ubiquitin

Indexed keywords

AMINO ACID; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; MUSCLE PROTEIN; MYOSTATIN; PROTEASOME; PROTEIN KINASE B; SMAD2 PROTEIN; SMAD3 PROTEIN; STAT3 PROTEIN; TRANSCRIPTION FACTOR FOXO; TRANSFORMING GROWTH FACTOR BETA; UBIQUITIN; PROTEIN;

AUTOPHAGY; CACHEXIA; GLUCONEOGENESIS; HUMAN; LYSOSOME; MUSCLE ATROPHY; MUSCLE GROWTH; NONHUMAN; PATHOGENESIS; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; REVIEW; ANIMAL; COMPLICATION; METABOLISM; NEOPLASM; SIGNAL TRANSDUCTION;

ANIMALS; CACHEXIA; HUMANS; MUSCULAR ATROPHY; NEOPLASMS; PROTEINS; PROTEOLYSIS; SIGNAL TRANSDUCTION;

EID: 84947574594     PISSN: 10849521     EISSN: 10963634     Source Type: Journal    
DOI: 10.1016/j.semcdb.2015.11.002     Document Type: Review

References (150)

1. Fearon K., Strasser F., Anker S.D., Bosaeus I., Bruera E., Fainsinger R.L., et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011, 12:489-495.
2. von Haehling S., Anker S.D. Cachexia as a major underestimated and unmet medical need: facts and numbers. J. Cachexia Sarcopenia Muscle 2010, 1:1-5.
3. Muscaritoli M., Anker S.D., Argiles J., Aversa Z., Bauer J.M., Biolo G., et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) "cachexia-anorexia in chronic wasting diseases" and "nutrition in geriatrics". Clin. Nutr. 2010, 29:154-159.
4. Fearon K.C. Cancer cachexia and fat-muscle physiology. N. Engl. J. Med. 2011, 365:565-567.
5. Wesseltoft-Rao N., Hjermstad M.J., Ikdahl T., Dajani O., Ulven S.M., Iversen P.O., et al. Comparing two classifications of cancer cachexia and their association with survival in patients with unresected pancreatic cancer. Nutr. Cancer 2015, 67:472-480.
6. Zhou X., Wang J.L., Lu J., Song Y., Kwak K.S., Jiao Q., et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 2010, 142:531-543.
7. Papageorgopoulos C., Caldwell K., Schweingrubber H., Neese R.A., Shackleton C.H., Hellerstein M. Measuring synthesis rates of muscle creatine kinase and myosin with stable isotopes and mass spectrometry. Anal. Biochem. 2002, 309:1-10.
8. Drexler H.C., Ruhs A., Konzer A., Mendler L., Bruckskotten M., Looso M., et al. On marathons and Sprints: an integrated quantitative proteomics and transcriptomics analysis of differences between slow and fast muscle fibers. Mol. Cell Proteom. 2012, 11. M111 010801.
9. Pallafacchina G., Calabria E., Serrano A.L., Kalhovde J.M., Schiaffino S. A protein kinase B-dependent and rapamycin-sensitive pathway controls skeletal muscle growth but not fiber type specification. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:9213-9218.
10. Raffaello A., Milan G., Masiero E., Carnio S., Lee D., Lanfranchi G., et al. JunB transcription factor maintains skeletal muscle mass and promotes hypertrophy. J. Cell Biol. 2010, 191:101-113.
11. Bonaldo P., Sandri M. Cellular and molecular mechanisms of muscle atrophy. Dis. Model Mech. 2013, 6:25-39.
12. Quy P.N., Kuma A., Pierre P., Mizushima N. Proteasome-dependent activation of mammalian target of rapamycin complex 1 (mTORC1) is essential for autophagy suppression and muscle remodeling following denervation. J. Biol. Chem. 2013, 288:1125-1134.
13. Bodine S.C., Latres E., Baumhueter S., Lai V.K., Nunez L., Clarke B.A., et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001, 294:1704-1708.
14. Lapierre L.R., Kumsta C., Sandri M., Ballabio A., Hansen M. Transcriptional and epigenetic regulation of autophagy in aging. Autophagy 2015, 11:867-880.
15. Bechet D., Tassa A., Taillandier D., Combaret L., Attaix D. Lysosomal proteolysis in skeletal muscle. Int. J. Biochem. Cell Biol. 2005, 37:2098-2114.
16. Deval C., Mordier S., Obled C., Bechet D., Combaret L., Attaix D., et al. Identification of cathepsin L as a differentially expressed message associated with skeletal muscle wasting. Biochem. J. 2001, 360:143-150.
17. Tassa A., Roux M.P., Attaix D., Bechet D.M. Class III phosphoinositide 3-kinase-Beclin1 complex mediates the amino acid-dependent regulation of autophagy in C2C12 myotubes. Biochem. J. 2003, 376:577-586.
18. Penna F., Costamagna D., Pin F., Camperi A., Fanzani A., Chiarpotto E.M., et al. Autophagic degradation contributes to muscle wasting in cancer cachexia. Am. J. Pathol. 2013, 182:1367-1378.
19. Mammucari C., Milan G., Romanello V., Masiero E., Rudolf R., Del Piccolo P., et al. FoxO3 controls autophagy in skeletal muscle in vivo. Cell Metab. 2007, 6:458-471.
20. Mizushima N., Yamamoto A., Matsui M., Yoshimori T., Ohsumi Y. In vivo analysis of autophagy in response to nutrient starvation using transgenic mice expressing a fluorescent autophagosome marker. Mol. Biol. Cell 2004, 15:1101-1111.
21. Grumati P., Coletto L., Sabatelli P., Cescon M., Angelin A., Bertaggia E., et al. Autophagy is defective in collagen VI muscular dystrophies, and its reactivation rescues myofiber degeneration. Nat. Med. 2010, 16:1313-1320.
22. Wohlgemuth S.E., Seo A.Y., Marzetti E., Lees H.A., Leeuwenburgh C. Skeletal muscle autophagy and apoptosis during aging: effects of calorie restriction and life-long exercise. Exp. Gerontol. 2010, 45:138-148.
23. Mofarrahi M., Sigala I., Guo Y., Godin R., Davis E.C., Petrof B., et al. Autophagy and skeletal muscles in sepsis. PLoS ONE 2012, 7:e47265.
24. Derde S., Vanhorebeek I., Guiza F., Derese I., Gunst J., Fahrenkrog B., et al. Early parenteral nutrition evokes a phenotype of autophagy deficiency in liver and skeletal muscle of critically ill rabbits. Endocrinology 2012, 153:2267-2276.
25. Qiu J., Tsien C., Thapalaya S., Narayanan A., Weihl C.C., Ching J.K., et al. Hyperammonemia-mediated autophagy in skeletal muscle contributes to sarcopenia of cirrhosis. Am. J. Physiol. Endocrinol. Metab. 2012, 303:E983-E993.
26. Smuder A.J., Kavazis A.N., Min K., Powers S.K. Exercise protects against doxorubicin-induced oxidative stress and proteolysis in skeletal muscle. J. Appl. Physiol. 2011, 110:935-942.
27. Brocca L., Cannavino J., Coletto L., Biolo G., Sandri M., Bottinelli R., et al. The time course of the adaptations of human muscle proteome to bed rest and the underlying mechanisms. J. Physiol. 2012, 590:5211-5230.
28. O'Leary M.F., Vainshtein A., Carter H.N., Zhang Y., Hood D.A. Denervation-induced mitochondrial dysfunction and autophagy in skeletal muscle of apoptosis-deficient animals. Am. J. Physiol. Cell Physiol. 2012, 303:C447-C454.
29. Zhao J., Brault J.J., Schild A., Cao P., Sandri M., Schiaffino S., et al. FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metab. 2007, 6:472-483.
30. Nascimbeni A.C., Fanin M., Masiero E., Angelini C., Sandri M. The role of autophagy in the pathogenesis of glycogen storage disease type II (GSDII). Cell Death Differ. 2012, 19:1698-1708.
31. De Palma C., Morisi F., Cheli S., Pambianco S., Cappello V., Vezzoli M., et al. Autophagy as a new therapeutic target in Duchenne muscular dystrophy. Cell Death Dis. 2012, 3:e418.
32. Sandri M., Coletto L., Grumati P., Bonaldo P. Misregulation of autophagy and protein degradation systems in myopathies and muscular dystrophies. J. Cell Sci. 2013, 126:5325-5333.
33. Wenz T., Rossi S.G., Rotundo R.L., Spiegelman B.M., Moraes C.T. Increased muscle PGC-1alpha expression protects from sarcopenia and metabolic disease during aging. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:20405-20410.
34. Carnio S., LoVerso F., Baraibar M.A., Longa E., Khan M.M., Maffei M., et al. Autophagy impairment in muscle induces neuromuscular junction degeneration and precocious aging. Cell Rep. 2014, 8:1509-1521.
35. Chacon-Cabrera A., Fermoselle C., Urtreger A.J., Mateu-Jimenez M., Diament M.J., de Kier Joffe E.D., et al. Pharmacological strategies in lung cancer-induced cachexia: effects on muscle proteolysis, autophagy, structure, and weakness. J. Cell Physiol. 2014, 229:1660-1672.
36. Tardif N., Klaude M., Lundell L., Thorell A., Rooyackers O. Autophagic-lysosomal pathway is the main proteolytic system modified in the skeletal muscle of esophageal cancer patients. Am. J. Clin. Nutr. 2013, 98:1485-1492.
37. Johns N., Hatakeyama S., Stephens N.A., Degen M., Degen S., Frieauff W., et al. Clinical classification of cancer cachexia: phenotypic correlates in human skeletal muscle. PLoS ONE 2014, 9:e83618.
38. Wang H., Sun H.Q., Zhu X., Zhang L., Albanesi J., Levine B., et al. GABARAPs regulate PI4P-dependent autophagosome:lysosome fusion. Proc. Natl. Acad. Sci. U.S.A. 2015, 112:7015-7020.
39. Stephens N.A., Skipworth R.J., Gallagher I.J., Greig C.A., Guttridge D.C., Ross J.A., et al. Evaluating potential biomarkers of cachexia and survival in skeletal muscle of upper gastrointestinal cancer patients. J. Cachexia Sarcopenia Muscle 2015, 6:53-61.
40. Puig-Vilanova E., Rodriguez D.A., Lloreta J., Ausin P., Pascual-Guardia S., Broquetas J., et al. Oxidative stress, redox signaling pathways, and autophagy in cachectic muscles of male patients with advanced COPD and lung cancer. Free Radical Biol. Med. 2015, 79:91-108.
41. Karsli-Uzunbas G., Guo J.Y., Price S., Teng X., Laddha S.V., Khor S., et al. Autophagy is required for glucose homeostasis and lung tumor maintenance. Cancer Discov. 2014, 4:914-927.
42. Masiero E., Agatea L., Mammucari C., Blaauw B., Loro E., Komatsu M., et al. Autophagy is required to maintain muscle mass. Cell Metab. 2009, 10:507-515.
43. Bujak A.L., Crane J.D., Lally J.S., Ford R.J., Kang S.J., Rebalka I.A., et al. AMPK activation of muscle autophagy prevents fasting-induced hypoglycemia and myopathy during aging. Cell Metab. 2015, 21:883-890.
44. Castets P., Lin S., Rion N., Di Fulvio S., Romanino K., Guridi M., et al. Sustained activation of mTORC1 in skeletal muscle inhibits constitutive and starvation-induced autophagy and causes a severe, late-onset myopathy. Cell Metab. 2013, 17:731-744.
45. Raben N., Hill V., Shea L., Takikita S., Baum R., Mizushima N., et al. Suppression of autophagy in skeletal muscle uncovers the accumulation of ubiquitinated proteins and their potential role in muscle damage in Pompe disease. Hum. Mol. Genet. 2008, 17:3897-3908.
46. Nemazanyy I., Blaauw B., Paolini C., Caillaud C., Protasi F., Mueller A., et al. Defects of Vps15 in skeletal muscles lead to autophagic vacuolar myopathy and lysosomal disease. EMBO Mol. Med. 2013, 5:870-890.
47. Battaglini C.L., Hackney A.C., Goodwin M.L. Cancer cachexia: muscle physiology and exercise training. Cancer (Basel) 2012, 4:1247-1251.
48. Jones L.W., Demark-Wahnefried W. Diet, exercise, and complementary therapies after primary treatment for cancer. Lancet Oncol. 2006, 7:1017-1026.
49. Grumati P., Coletto L., Schiavinato A., Castagnaro S., Bertaggia E., Sandri M., et al. Physical exercise stimulates autophagy in normal skeletal muscles but is detrimental for collagen VI-deficient muscles. Autophagy 2011, 7:1415-1423.
50. Jamart C., Benoit N., Raymackers J.M., Kim H.J., Kim C.K., Francaux M. Autophagy-related and autophagy-regulatory genes are induced in human muscle after ultraendurance exercise. Eur. J. Appl. Physiol. 2012, 112:3173-3177.
51. Jamart C., Francaux M., Millet G.Y., Deldicque L., Frere D., Feasson L. Modulation of autophagy and ubiquitin-proteasome pathways during ultra-endurance running. J. Appl. Physiol. 2012, 112:1529-1537.
52. Luo L., Lu A.M., Wang Y., Hong A., Chen Y., Hu J., et al. Chronic resistance training activates autophagy and reduces apoptosis of muscle cells by modulating IGF-1 and its receptors, Akt/mTOR and Akt/FOXO3a signaling in aged rats. Exp Gerontol. 2013, 48:427-436.
53. He C., Bassik M.C., Moresi V., Sun K., Wei Y., Zou Z., et al. Exercise-induced BCL2-regulated autophagy is required for muscle glucose homeostasis. Nature 2012, 481:511-515.
54. Schwalm C., Jamart C., Benoit N., Naslain D., Premont C., Prevet J., et al. Activation of autophagy in human skeletal muscle is dependent on exercise intensity and AMPK activation. FASEB J. 2015, 29:3515-3526.
55. Lo Verso F., Carnio S., Vainshtein A., Sandri M. Autophagy is not required to sustain exercise and PRKAA1/AMPK activity but is important to prevent mitochondrial damage during physical activity. Autophagy 2014, 10:1883-1894.
56. Lecker S.H., Jagoe R.T., Gilbert A., Gomes M., Baracos V., Bailey J., et al. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J. 2004, 18:39-51.
57. Kedar V., McDonough H., Arya R., Li H.H., Rockman H.A., Patterson C. Muscle-specific RING finger 1 is a bona fide ubiquitin ligase that degrades cardiac troponin I. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:18135-18140.
58. Fielitz J., Kim M.S., Shelton J.M., Latif S., Spencer J.A., Glass D.J., et al. Myosin accumulation and striated muscle myopathy result from the loss of muscle RING finger 1 and 3. J. Clin. Invest. 2007, 117:2486-2495.
59. Clarke B.A., Drujan D., Willis M.S., Murphy L.O., Corpina R.A., Burova E., et al. The E3 Ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle. Cell Metab. 2007, 6:376-385.
60. Polge C., Heng A.E., Jarzaguet M., Ventadour S., Claustre A., Combaret L., et al. Muscle actin is polyubiquitinylated in vitro and in vivo and targeted for breakdown by the E3 ligase MuRF1. FASEB J. 2011, 25:3790-3802.
61. Cohen S., Brault J.J., Gygi S.P., Glass D.J., Valenzuela D.M., Gartner C., et al. During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation. J. Cell Biol. 2009, 185:1083-1095.
62. Csibi A., Cornille K., Leibovitch M.P., Poupon A., Tintignac L.A., Sanchez A.M., et al. The translation regulatory subunit eIF3f controls the kinase-dependent mTOR signaling required for muscle differentiation and hypertrophy in mouse. PLoS ONE 2010, 5:e8994.
63. Tintignac L.A., Lagirand J., Batonnet S., Sirri V., Leibovitch M.P., Leibovitch S.A. Degradation of MyoD mediated by the SCF (MAFbx) ubiquitin ligase. J. Biol. Chem. 2005, 280:2847-2856.
64. Lokireddy S., Wijesoma I.W., Sze S.K., McFarlane C., Kambadur R., Sharma M. Identification of atrogin-1-targeted proteins during the myostatin-induced skeletal muscle wasting. Am. J. Physiol. Cell Physiol. 2012, 303:C512-C529.
65. Li H.H., Kedar V., Zhang C., McDonough H., Arya R., Wang D.Z., et al. Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex. J. Clin. Invest. 2004, 114:1058-1071.
66. Zaglia T., Milan G., Ruhs A., Franzoso M., Bertaggia E., Pianca N., et al. Atrogin-1 deficiency promotes cardiomyopathy and premature death via impaired autophagy. J. Clin. Invest. 2014, 124:2410-2424.
67. Wu Z., Lee S.T., Qiao Y., Li Z., Lee P.L., Lee Y.J., et al. Polycomb protein EZH2 regulates cancer cell fate decision in response to DNA damage. Cell. Death Differ. 2011, 18:1771-1779.
68. Lei K.F., Liu B.Y., Wang Y.F., Chen X.H., Yu B.Q., Guo Y., et al. SerpinB5 interacts with KHDRBS3 and FBXO32 in gastric cancer cells. Oncol. Rep. 2011, 26:1115-1120.
69. Chou J.L., Su H.Y., Chen L.Y., Liao Y.P., Hartman-Frey C., Lai Y.H., et al. Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer. Lab. Invest. 2010, 90:414-425.
70. Frolov A., Chahwan S., Ochs M., Arnoletti J.P., Pan Z.Z., Favorova O., et al. Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumors. Mol. Cancer Ther. 2003, 2:699-709.
71. Mei Z., Zhang D., Hu B., Wang J., Shen X., Xiao W. FBXO32 targets c-Myc for proteasomal degradation and inhibits c-Myc activity. J. Biol. Chem. 2015, 290:16202-16214.
72. Baehr L.M., Furlow J.D., Bodine S.C. Muscle sparing in muscle RING finger 1 null mice: response to synthetic glucocorticoids. J. Physiol. 2011, 589:4759-4776.
73. Hwee D.T., Baehr L.M., Philp A., Baar K., Bodine S.C. Maintenance of muscle mass and load-induced growth in Muscle RING Finger 1 null mice with age. Aging Cell 2014, 13:92-101.
74. Sandri M., Barberi L., Bijlsma A.Y., Blaauw B., Dyar K.A., Milan G., et al. Signalling pathways regulating muscle mass in ageing skeletal muscle. The role of the IGF1-Akt-mTOR-FoxO pathway. Biogerontology 2013, 14:303-323.
75. Gomes A.V., Waddell D.S., Siu R., Stein M., Dewey S., Furlow J.D., et al. Upregulation of proteasome activity in muscle RING finger 1-null mice following denervation. FASEB J. 2012, 26:2986-2999.
76. Sartori R., Schirwis E., Blaauw B., Bortolanza S., Zhao J., Enzo E., et al. BMP signaling controls muscle mass. Nat. Genet. 2013, 45:1309-1318.
77. Cong H., Sun L., Liu C., Tien P. Inhibition of atrogin-1/MAFbx expression by adenovirus-delivered small hairpin RNAs attenuates muscle atrophy in fasting mice. Hum. Gene Ther. 2011, 22:313-324.
78. Paul P.K., Gupta S.K., Bhatnagar S., Panguluri S.K., Darnay B.G., Choi Y., et al. Targeted ablation of TRAF6 inhibits skeletal muscle wasting in mice. J. Cell Biol. 2010, 191:1395-1411.
79. Sun Y.S., Ye Z.Y., Qian Z.Y., Xu X.D., Hu J.F. Expression of TRAF6 and ubiquitin mRNA in skeletal muscle of gastric cancer patients. J. Exp. Clin. Cancer Res. 2012, 31:81.
80. Kirkin V., Lamark T., Sou Y.S., Bjorkoy G., Nunn J.L., Bruun J.A., et al. A role for NBR1 in autophagosomal degradation of ubiquitinated substrates. Mol. Cell 2009, 33:505-516.
81. Komatsu M., Waguri S., Koike M., Sou Y.S., Ueno T., Hara T., et al. Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice. Cell 2007, 131:1149-1163.
82. Pankiv S., Clausen T.H., Lamark T., Brech A., Bruun J.A., Outzen H., et al. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J. Biol. Chem. 2007, 282:24131-24145.
83. Paul P.K., Bhatnagar S., Mishra V., Srivastava S., Darnay B.G., Choi Y., et al. The E3 ubiquitin ligase TRAF6 intercedes in starvation-induced skeletal muscle atrophy through multiple mechanisms. Mol. Cell Biol. 2012, 32:1248-1259.
84. Kumar A., Bhatnagar S., Paul P.K. TWEAK and TRAF6 regulate skeletal muscle atrophy. Curr. Opin. Clin. Nutr. Metab. Care 2012, 15:233-239.
85. Nazio F., Strappazzon F., Antonioli M., Bielli P., Cianfanelli V., Bordi M., et al. mTOR inhibits autophagy by controlling ULK1 ubiquitylation, self-association and function through AMBRA1 and TRAF6. Nat. Cell Biol. 2013, 15:406-416.
86. Milan G., Romanello V., Pescatore F., Armani A., Paik J.H., Frasson L., et al. Regulation of autophagy and the ubiquitin-proteasome system by the FoxO transcriptional network during muscle atrophy. Nat. Commun. 2015, 6:6670.
87. Cornwell E.W., Mirbod A., Wu C.L., Kandarian S.C., Jackman R.W. C26 cancer-induced muscle wasting is IKKbeta-dependent and NF-kappaB-independent. PLoS ONE 2014, 9:e87776.
88. Judge S.M., Wu C.L., Beharry A.W., Roberts B.M., Ferreira L.F., Kandarian S.C., et al. Genome-wide identification of FoxO-dependent gene networks in skeletal muscle during C26 cancer cachexia. BMC Cancer 2014, 14:997.
89. Gomes M.D., Lecker S.H., Jagoe R.T., Navon A., Goldberg A.L. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:14440-14445.
90. Combaret L., Adegoke O.A., Bedard N., Baracos V., Attaix D., Wing S.S. USP19 is a ubiquitin-specific protease regulated in rat skeletal muscle during catabolic states. Am. J. Physiol. Endocrinol. Metab. 2005, 288:E693-E700.
91. Bedard N., Jammoul S., Moore T., Wykes L., Hallauer P.L., Hastings K.E., et al. Inactivation of the ubiquitin-specific protease 19 deubiquitinating enzyme protects against muscle wasting. FASEB J. 2015, 29:3889-3898.
92. Sundaram P., Pang Z., Miao M., Yu L., Wing S.S. USP19-deubiquitinating enzyme regulates levels of major myofibrillar proteins in L6 muscle cells. Am. J. Physiol. Endocrinol. Metab. 2009, 297:E1283-E1290.
93. Sandri M., Sandri C., Gilbert A., Skurk C., Calabria E., Picard A., et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004, 117:399-412.
94. Reed S.A., Sandesara P.B., Senf S.M., Judge A.R. Inhibition of FoxO transcriptional activity prevents muscle fiber atrophy during cachexia and induces hypertrophy. FASEB J. 2012, 26:987-1000.
95. Skorokhod A., Bachmann J., Giese N.A., Martignoni M.E., Krakowski-Roosen H. Real-imaging cDNA-AFLP transcript profiling of pancreatic cancer patients: Egr-1 as a potential key regulator of muscle cachexia. BMC Cancer 2012, 12:265.
96. Allen D.L., Unterman T.G. Regulation of myostatin expression and myoblast differentiation by FoxO and SMAD transcription factors. Am. J. Physiol. Cell Physiol. 2007, 292:C188-C199.
97. Liu C.M., Yang Z., Liu C.W., Wang R., Tien P., Dale R., et al. Effect of RNA oligonucleotide targeting Foxo-1 on muscle growth in normal and cancer cachexia mice. Cancer Gene Ther. 2007, 14:945-952.
98. Tang H., Inoki K., Lee M., Wright E., Khuong A., Sugiarto S., et al. mTORC1 promotes denervation-induced muscle atrophy through a mechanism involving the activation of FoxO and E3 ubiquitin ligases. Sci. Signal 2014, 7:ra18.
99. Zhang G., Jin B., Li Y.P. C/EBPbeta mediates tumour-induced ubiquitin ligase atrogin1/MAFbx upregulation and muscle wasting. EMBO J. 2011, 30:4323-4335.
100. Bonetto A., Aydogdu T., Jin X., Zhang Z., Zhan R., Puzis L., et al. JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. Am. J. Physiol. Endocrinol. Metab. 2012, 303:E410-E421.
101. Silva K.A., Dong J., Dong Y., Schor N., Tweardy D.J., Zhang L., et al. Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia. J. Biol. Chem. 2015, 290:11177-11187.
102. Choi M.C., Cohen T.J., Barrientos T., Wang B., Li M., Simmons B.J., et al. A direct HDAC4-MAP kinase crosstalk activates muscle atrophy program. Mol. Cell 2012, 47:122-132.
103. Andres-Mateos E., Brinkmeier H., Burks T.N., Mejias R., Files D.C., Steinberger M., et al. Activation of serum/glucocorticoid-induced kinase 1 (SGK1) is important to maintain skeletal muscle homeostasis and prevent atrophy. EMBO Mol. Med. 2013, 5:80-91.
104. Brunet A., Park J., Tran H., Hu L.S., Hemmings B.A., Greenberg M.E. Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a). Mol. Cell Biol. 2001, 21:952-965.
105. Greer E.L., Oskoui P.R., Banko M.R., Maniar J.M., Gygi M.P., Gygi S.P., et al. The energy sensor AMP-activated protein kinase directly regulates the mammalian FOXO3 transcription factor. J. Biol. Chem. 2007, 282:30107-30119.
106. Asada S., Daitoku H., Matsuzaki H., Saito T., Sudo T., Mukai H., et al. Mitogen-activated protein kinases, Erk and p38, phosphorylate and regulate Foxo1. Cell Signal. 2007, 19:519-527.
107. Yang J.Y., Zong C.S., Xia W., Yamaguchi H., Ding Q., Xie X., et al. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat. Cell Biol. 2008, 10:138-148.
108. Essers M.A., Weijzen S., de Vries-Smits A.M., Saarloos I., de Ruiter N.D., Bos J.L., et al. FOXO transcription factor activation by oxidative stress mediated by the small GTPase Ral and JNK. EMBO J. 2004, 23:4802-4812.
109. Oh S.W., Mukhopadhyay A., Svrzikapa N., Jiang F., Davis R.J., Tissenbaum H.A. JNK regulates lifespan in Caenorhabditis elegans by modulating nuclear translocation of forkhead transcription factor/DAF-16. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:4494-4499.
110. Wei B., Dui W., Liu D., Xing Y., Yuan Z., Ji G. MST1, a key player, in enhancing fast skeletal muscle atrophy. BMC Biol. 2013, 11:12.
111. Lehtinen M.K., Yuan Z., Boag P.R., Yang Y., Villen J., Becker E.B., et al. A conserved MST-FOXO signaling pathway mediates oxidative-stress responses and extends life span. Cell 2006, 125:987-1001.
112. Hu M.C., Lee D.F., Xia W., Golfman L.S., Ou-Yang F., Yang J.Y., et al. IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 2004, 117:225-237.
113. Webb A.E., Brunet A. FOXO transcription factors: key regulators of cellular quality control. Trends Biochem. Sci. 2014, 39:159-169.
114. Bertaggia E., Coletto L., Sandri M., Posttranslational modifications control FoxO3 activity during denervation Am. J. Physiol. Cell Physiol. 2012, 302:C587-C596.
115. Senf S.M., Sandesara P.B., Reed S.A., Judge A.R. p300 Acetyltransferase activity differentially regulates the localization and activity of the FOXO homologues in skeletal muscle. Am. J. Physiol. Cell Physiol. 2011, 300:C1490-C1501.
116. Beharry A.W., Sandesara P.B., Roberts B.M., Ferreira L.F., Senf S.M., Judge A.R. HDAC1 activates FoxO and is both sufficient and required for skeletal muscle atrophy. J. Cell Sci. 2014, 127:1441-1453.
117. Lee D., Goldberg A.L. SIRT1 protein, by blocking the activities of transcription factors FoxO1 and FoxO3, inhibits muscle atrophy and promotes muscle growth. J. Biol. Chem. 2013, 288:30515-30526.
118. Romanello V., Guadagnin E., Gomes L., Roder I., Sandri C., Petersen Y., et al. Mitochondrial fission and remodelling contributes to muscle atrophy. EMBO J. 2010, 29:1774-1785.
119. Brault J.J., Jespersen J.G., Goldberg A.L. Peroxisome proliferator-activated receptor gamma coactivator 1alpha or 1beta overexpression inhibits muscle protein degradation, induction of ubiquitin ligases, and disuse atrophy. J. Biol. Chem. 2010, 285:19460-19471.
120. Raffaello A., Laveder P., Romualdi C., Bean C., Toniolo L., Germinario E., et al. Denervation in murine fast-twitch muscle: short-term physiological changes and temporal expression profiling. Physiol. Genomics 2006, 25:60-74.
121. Sandri M., Lin J., Handschin C., Yang W., Arany Z.P., Lecker S.H., et al. PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:16260-16265.
122. Waddell D.S., Baehr L.M., van den Brandt J., Johnsen S.A., Reichardt H.M., Furlow J.D., et al. The glucocorticoid receptor and FOXO1 synergistically activate the skeletal muscle atrophy-associated MuRF1 gene. Am. J. Physiol. Endocrinol. Metab. 2008, 295:E785-E797.
123. Okada K., Naito A.T., Higo T., Nakagawa A., Shibamoto M., Sakai T., et al. Wnt/beta-catenin signaling contributes to skeletal myopathy in heart failure via direct interaction with forkhead box O. Circ. Heart Fail. 2015, 8:799-808.
124. Shimizu N., Maruyama T., Yoshikawa N., Matsumiya R., Ma Y., Ito N., et al. A muscle-liver-fat signalling axis is essential for central control of adaptive adipose remodelling. Nat, Commun. 2015, 6:6693.
125. Qin W., Pan J., Qin Y., Lee D.N., Bauman W.A., Cardozo C. Identification of functional glucocorticoid response elements in the mouse FoxO1 promoter. Biochem. Biophys. Res. Commun. 2014, 450:979-983.
126. Shimizu N., Yoshikawa N., Ito N., Maruyama T., Suzuki Y., Takeda S., et al. Crosstalk between glucocorticoid receptor and nutritional sensor mTOR in skeletal muscle. Cell Metab. 2011, 13:170-182.
127. Porporato P.E., Filigheddu N., Reano S., Ferrara M., Angelino E., Gnocchi V.F., et al. Acylated and unacylated ghrelin impair skeletal muscle atrophy in mice. J. Clin. Invest. 2013, 123:611-622.
128. Garcia J.M., Boccia R.V., Graham C.D., Yan Y., Duus E.M., Allen S., et al. Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials. Lancet Oncol. 2015, 16:108-116.
129. Chen J.A., Splenser A., Guillory B., Luo J., Mendiratta M., Belinova B., et al. Ghrelin prevents tumour- and cisplatin-induced muscle wasting: characterization of multiple mechanisms involved. J. Cachexia Sarcopenia Muscle 2015, 6:132-143.
130. Cai D., Frantz J.D., Tawa N.E., Melendez P.A., Oh B.C., Lidov H.G., et al. IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell 2004, 119:285-298.
131. Mourkioti F., Kratsios P., Luedde T., Song Y.H., Delafontaine P., Adami R., et al. Targeted ablation of IKK2 improves skeletal muscle strength, maintains mass, and promotes regeneration. J. Clin. Invest. 2006, 116:2945-2954.
132. Lee D., Goldberg A.L. Muscle wasting in fasting requires activation of NF-kappaB and inhibition of AKT/mTOR by the protein acetylase, GCN5. J. Biol. Chem. 2015, pii: jbc.M115.685164.
133. Zhang L., Pan J., Dong Y., Tweardy D.J., Garibotto G., Mitch W.E. Stat3 activation links a C/EBPdelta to myostatin pathway to stimulate loss of muscle mass. Cell Metab. 2013, 18:368-379.
134. Yamada E., Bastie C.C., Koga H., Wang Y., Cuervo A.M., Pessin J.E. Mouse skeletal muscle fiber-type-specific macroautophagy and muscle wasting are regulated by a Fyn/STAT3/Vps34 signaling pathway. Cell Rep. 2012, 1:557-569.
135. Murphy K.T., Chee A., Gleeson B.G., Naim T., Swiderski K., Koopman R., et al. Antibody-directed myostatin inhibition enhances muscle mass and function in tumor-bearing mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2011, 301:R716-R726.
136. Benny Klimek M.E., Aydogdu T., Link M.J., Pons M., Koniaris L.G., Zimmers T.A. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem. Biophys. Res. Commun. 2010, 391:1548-1554.
137. Busquets S., Toledo M., Orpi M., Massa D., Porta M., Capdevila E., et al. Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance. J. Cachexia Sarcopenia Muscle 2012, 3:37-43.
138. Gallot Y.S., Durieux A.C., Castells J., Desgeorges M.M., Vernus B., Plantureux L., et al. Myostatin gene inactivation prevents skeletal muscle wasting in cancer. Cancer Res. 2014, 74:7344-7356.
139. Loumaye A., de Barsy M., Nachit M., Lause P., Frateur L., van Maanen A., et al. Role of Activin A and myostatin in human cancer cachexia. J. Clin. Endocrinol. Metab. 2015, 100:2030-2038.
140. Chen J.L., Walton K.L., Winbanks C.E., Murphy K.T., Thomson R.E., Makanji Y., et al. Elevated expression of activins promotes muscle wasting and cachexia. FASEB J. 2014, 28:1711-1723.
141. Sartori R., Milan G., Patron M., Mammucari C., Blaauw B., Abraham R., et al. Smad2 and 3 transcription factors control muscle mass in adulthood. Am. J. Physiol. Cell Physiol. 2009, 296:C1248-C1257.
142. Trendelenburg A.U., Meyer A., Rohner D., Boyle J., Hatakeyama S., Glass D.J. Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size. Am. J. Physiol. Cell Physiol. 2009, 296:C1258-C1270.
143. Lokireddy S., McFarlane C., Ge X., Zhang H., Sze S.K., Sharma M., et al. Myostatin induces degradation of sarcomeric proteins through a Smad3 signaling mechanism during skeletal muscle wasting. Mol. Endocrinol. 2011, 25:1936-1949.
144. Winbanks C.E., Weeks K.L., Thomson R.E., Sepulveda P.V., Beyer C., Qian H.W., et al. Follistatin-mediated skeletal muscle hypertrophy is regulated by Smad3 and mTOR independently of myostatin. J. Cell Biol. 2012, 197:997-1008.
145. Goodman C.A., McNally R.M., Hoffmann F.M., Hornberger T.A. Smad3 induces Atrogin-1 Inhibits mTOR and protein synthesis, and promotes muscle atrophy in vivo. Mol. Endocrinol. 2013, 27:1946-1957.
146. Amirouche A., Durieux A.C., Banzet S., Koulmann N., Bonnefoy R., Mouret C., et al. Down-regulation of Akt/mammalian target of rapamycin signaling pathway in response to myostatin overexpression in skeletal muscle. Endocrinology 2009, 150:286-294.
147. Hulmi J.J., Oliveira B.M., Silvennoinen M., Hoogaars W.M.H., Ma H.Q., Pierre P., et al. Muscle protein synthesis, mTORC1/MAPK/Hippo signaling, and capillary density are altered by blocking of myostatin and activins. Am. J. Physiol-Endoc. Metab. 2013, 304:E41-E50.
148. Rodriguez J., Vernus B., Toubiana M., Jublanc E., Tintignac L., Leibovitch S., et al. Myostatin inactivation increases myotube size through regulation of translational initiation machinery. J. Cell. Biochem. 2011, 112:3531-3542.
149. Welle S., Burgess K., Mehta S. Stimulation of skeletal muscle myofibrillar protein synthesis, p70 S6 kinase phosphorylation, and ribosomal protein S6 phosphorylation by inhibition of myostatin in mature mice. Am. J. Physiol-Endoc. Metab. 2009, 296. E567-E72.
150. Winbanks C.E., Chen J.L., Qian H., Liu Y., Bernardo B.C., Beyer C., et al. The bone morphogenetic protein axis is a positive regulator of skeletal muscle mass. J. Cell Biol. 2013, 203:345-357.